2026 ASCO Poster: Plasma Epigenomic Profiling Identifies Mechanisms of Sensitivity and Resistance to Tepotinib in METex14 Skipping Metastatic NSCLC
2026 ASCO Poster: Plasma Epigenomic Profiling Identifies Mechanisms of Sensitivity and Resistance to Tepotinib in METex14 Skipping Metastatic NSCLC
2026 ASCO Poster: Comprehensive Epigenomic Profiling of Plasma for Non-invasive Detection of MET Activation Uncovers MET-associated Biology in Patients with EGFR-mutated Advanced NSCLC and Progression on Osimertinib
2026 ASCO Poster: Comprehensive Epigenomic Profiling of Plasma for Non-invasive Detection of MET Activation Uncovers MET-associated Biology in Patients with EGFR-mutated Advanced NSCLC and Progression on Osimerti
2026 AACR Poster: Plasma-based comprehensive epigenomic profiling enables multiplexed prediction of target gene expression and detection of resistance mechanisms
2026 AACR Poster: Plasma-based comprehensive epigenomic profiling enables multiplexed prediction of target gene expression and detection of resistance mechanisms
2026 AACR Poster: A liquid biopsy assay of estrogen receptor activity predicts response to giredestrant in ER+/HER2− advanced breast cancer
2026 AACR Poster: A liquid biopsy assay of estrogen receptor activity predicts response to giredestrant in ER+/HER2− advanced breast cancer
2026 AACR Poster: Characterization of functional estrogen receptor (ER) dependence via comprehensive epigenomic liquid biopsy stratifies endocrine therapy (ET) responders with metastatic breast cancer (MBC)
2026 AACR Poster: Characterization of functional estrogen receptor (ER) dependence via comprehensive epigenomic liquid biopsy stratifies endocrine therapy (ET) responders with metastatic breast cancer (MBC)
2025 ESMO Poster: Comprehensive Epigenomic Profiling of Plasma ctDNA Enables Assessment of Drug Target Expression in SCLC
2025 ESMO Poster: Comprehensive Epigenomic Profiling of Plasma ctDNA Enables Assessment of Drug Target Expression in SCLC
2025 ASCO Poster: Robust characterization of response & resistance to 177Lu-PSMA-617 in mCRPC by plasma-based epigenomic profiling
2025 ASCO Poster: Robust characterization of response & resistance to 177Lu-PSMA-617 in mCRPC by plasma-based epigenomic profiling
2025 ASCO Poster: Cell-free circulating chromatin profiles enable epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer
2025 ASCO Poster: Cell-free circulating chromatin profiles enable epigenomic characterization of mechanisms of response and resistance to sacituzumab govitecan in breast cancer
2025 AACR Poster: Systematic and Robust Prediction of Gene Expression Using Comprehensive Epigenomic Profiling of Plasma cfDNA
2025 AACR Poster: Systematic and Robust Prediction of Gene Expression Using Comprehensive Epigenomic Profiling of Plasma cfDNA
2025 ASCO GU Poster: Epigenomic profiling of circulating chromatin for early detection and monitoring of neuroendocrine prostate cancer
2025 ASCO GU Poster: Epigenomic profiling of circulating chromatin for early detection and monitoring of neuroendocrine prostate cancer